LINSITINIB Insulin-like Growth Factor 1 Receptor Antagonist Insulin Receptor Antagonist Oncolytic

[摘要]：Linsitinib (OSI-906) is a novel, small-molecule, dual inhibitor of insulin-like growth factor 7 receptor (IGT-I receptor) and insulin receptor (IR). There is ample evidence that the ICE-I receptor is overexpressed in several epithelial and mesenchymal malignancies. Preclinical data support linsitinib as a single agent or in combination with cytotoxic chemotherapy for colorectal carcinoma, adrenocortical carcinoma and breast carcinoma, among other cancers. This review will evaluate the preclinical pharmacology, pharmacokinetics, drug interactions and clinical activity in phase I through phase Ill studies.

[全文传递流程]：

一般上传文献全文的时限在1个工作日内